Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant

Neurology. 1990 Nov;40(11):1797-8. doi: 10.1212/wnl.40.11.1797.

Abstract

We report the lst case of neuroleptic malignant syndrome occurring in a patient receiving desipramine, a tricyclic antidepressant, with no exposure to neuroleptics. Our case suggests that this syndrome may be caused by a central imbalance between norepinephrine and dopamine, and not by dopamine depletion alone.

Publication types

  • Case Reports

MeSH terms

  • Bromocriptine / therapeutic use
  • Dantrolene / therapeutic use
  • Desipramine / adverse effects*
  • Dopamine / metabolism
  • Drug Therapy, Combination
  • Female
  • Humans
  • Middle Aged
  • Neuroleptic Malignant Syndrome / drug therapy
  • Neuroleptic Malignant Syndrome / etiology*
  • Neuroleptic Malignant Syndrome / metabolism
  • Norepinephrine / metabolism

Substances

  • Bromocriptine
  • Dantrolene
  • Desipramine
  • Dopamine
  • Norepinephrine